Literature DB >> 33671013

Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.

Qun Wang1, Aurelia Vattai1, Theresa Vilsmaier1, Till Kaltofen1, Alexander Steger2, Doris Mayr3, Sven Mahner1, Udo Jeschke1,4, Helene Hildegard Heidegger1.   

Abstract

Cervical cancer is primarily caused by the infection of high-risk human papillomavirus (hrHPV). Moreover, tumor immune microenvironment plays a significant role in the tumorigenesis of cervical cancer. Therefore, it is necessary to comprehensively identify predictive biomarkers from immunogenomics associated with cervical cancer prognosis. The Cancer Genome Atlas (TCGA) public database has stored abundant sequencing or microarray data, and clinical data, offering a feasible and reliable approach for this study. In the present study, gene profile and clinical data were downloaded from TCGA, and the Immunology Database and Analysis Portal (ImmPort) database. Wilcoxon-test was used to compare the difference in gene expression. Univariate analysis was adopted to identify immune-related genes (IRGs) and transcription factors (TFs) correlated with survival. A prognostic prediction model was established by multivariate cox analysis. The regulatory network was constructed and visualized by correlation analysis and Cytoscape, respectively. Gene functional enrichment analysis was performed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). A total of 204 differentially expressed IRGs were identified, and 22 of them were significantly associated with the survival of cervical cancer. These 22 IRGs were actively involved in the JAK-STAT pathway. A prognostic model based on 10 IRGs (APOD, TFRC, GRN, CSK, HDAC1, NFATC4, BMP6, IL17RD, IL3RA, and LEPR) performed moderately and steadily in squamous cell carcinoma (SCC) patients with FIGO stage I, regardless of the age and grade. Taken together, a risk score model consisting of 10 novel genes capable of predicting survival in SCC patients was identified. Moreover, the regulatory network of IRGs associated with survival (SIRGs) and their TFs provided potential molecular targets.

Entities:  

Keywords:  KEGG; TCGA; bioinformatics analysis; cervical cancer; tumor immune

Mesh:

Substances:

Year:  2021        PMID: 33671013      PMCID: PMC7957482          DOI: 10.3390/ijms22052442

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  54 in total

1.  clusterProfiler: an R package for comparing biological themes among gene clusters.

Authors:  Guangchuang Yu; Li-Gen Wang; Yanyan Han; Qing-Yu He
Journal:  OMICS       Date:  2012-03-28

2.  Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.

Authors:  Yang Yang; Yuxin Che; Yan Zhao; Xuelian Wang
Journal:  Int Immunopharmacol       Date:  2019-02-08       Impact factor: 4.932

3.  The advent of human papillomavirus detection for cervical screening.

Authors:  Brian J Morris
Journal:  Curr Opin Obstet Gynecol       Date:  2019-10       Impact factor: 1.927

4.  ImmPort: disseminating data to the public for the future of immunology.

Authors:  Sanchita Bhattacharya; Sandra Andorf; Linda Gomes; Patrick Dunn; Henry Schaefer; Joan Pontius; Patty Berger; Vince Desborough; Tom Smith; John Campbell; Elizabeth Thomson; Ruth Monteiro; Patricia Guimaraes; Bryan Walters; Jeff Wiser; Atul J Butte
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

5.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma.

Authors:  Feng Ye; Yan Yu; Yuting Hu; Weiguo Lu; Xing Xie
Journal:  J Exp Clin Cancer Res       Date:  2010-06-18

7.  Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12.

Authors:  Antonella Rigo; Michele Gottardi; Alberto Zamò; Pierluigi Mauri; Massimiliano Bonifacio; Mauro Krampera; Ernesto Damiani; Giovanni Pizzolo; Fabrizio Vinante
Journal:  Mol Cancer       Date:  2010-10-14       Impact factor: 27.401

8.  HDAC1/DNMT3A-containing complex is associated with suppression of Oct4 in cervical cancer cells.

Authors:  Dongbo Liu; Peng Zhou; Li Zhang; Wei Gong; Gang Huang; Yingru Zheng; Fengtian He
Journal:  Biochemistry (Mosc)       Date:  2012-08       Impact factor: 2.487

9.  Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer.

Authors:  Vitor Hugo de Almeida; Isabella Dos Santos Guimarães; Lucas R Almendra; Araci M R Rondon; Tatiana M Tilli; Andréia C de Melo; Cinthya Sternberg; Robson Q Monteiro
Journal:  Oncotarget       Date:  2018-07-17

10.  [ARTICLE WITHDRAWN] Overexpression of MicroRNA-34a-5p Inhibits Proliferation and Promotes Apoptosis of Human Cervical Cancer Cells by Downregulation of Bcl-2.

Authors:  Xiufen Wang; Yucui Xie; Jing Wang
Journal:  Oncol Res       Date:  2017-08-30       Impact factor: 5.574

View more
  3 in total

1.  Development and verification of a hypoxia- and immune-associated prognosis signature for esophageal squamous cell carcinoma.

Authors:  Lian Lian; Shi-Bing Teng; You-You Xia; Xiao-Ming Shen; Yan Zheng; Shu-Guang Han; Wen-Jie Wang; Xue-Fei Xu; Chong Zhou
Journal:  J Gastrointest Oncol       Date:  2022-04

Review 2.  Recent knowledge of NFATc4 in oncogenesis and cancer prognosis.

Authors:  Qiu-Hua Zhong; Si-Wei Zha; Andy T Y Lau; Yan-Ming Xu
Journal:  Cancer Cell Int       Date:  2022-06-13       Impact factor: 6.429

3.  Metabolism-Relevant Molecular Classification Identifies Tumor Immune Microenvironment Characterization and Immunotherapeutic Effect in Cervical Cancer.

Authors:  Luyi Li; Hui Gao; Danhan Wang; Hao Jiang; Hongzhu Wang; Jiajian Yu; Xin Jiang; Changjiang Huang
Journal:  Front Mol Biosci       Date:  2021-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.